Skip to content

Modified Dixon sequential method to determine the half effective dose of oliceridine combined with propofol for hysteroscopy

Modified Dixon sequential method to determine the half effective dose of oliceridine combined with propofol for hysteroscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098967
Enrollment
Unknown
Registered
2025-03-17
Start date
2025-03-25
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Daytime hysteroscopy

Interventions

Case series:Oliceridine (modified sequential method) + propofol

Sponsors

Zigong Maternal and Child Health Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Women who will undergo intravenous anesthesia for hysteroscopy; 2. Aged 18-60 years, BMI 18-25 kg/m^2; 3. American Society of Anesthesiologists (ASA) classification I-II; 4. No obvious abnormality in the ECG, blood routine and electrolyte results before operation.

Exclusion criteria

Exclusion criteria: 1. Emergency patients; 2. Patients with abnormal functions such as heart, lung, liver, and kidney; 3. Patients with obstructive sleep apnea syndrome or difficult airway; 4. Patients with recent respiratory infection; 5. Those with a history of hypertension; 6. Those with a long-term history of taking sedative and analgesic drugs; 7. Patients with psychiatric diseases; 8. Those with known allergy to general anesthesia drugs. 9. All patients or family members sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Body movement response;Mean arterial pressure;Heart rate;Saturation of Peripheral Oxygen;

Countries

China

Contacts

Public ContactQin Liu

Zigong Maternal and Child Health Care Hospital

869422375@qq.com+86 139 8022 8886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026